The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury

Journal of Clinical Investigation

Volumn 111, Issue 4, 2003, Pages 469-478

  Yasukawa, Hideo ^a,b   Yajima, Toshitaka ^a,b   Duplain, Hervé ^a,b   Iwatate, Mitsuo ^a,b   Kido, Masakuni ^a   Hoshijima, Masahiko ^a,b   Weitzman, Matthew D ^c   Nakamura, Tomoyuki ^a,b   Woodard, Sarah ^a,b   Xiong, Dingding ^a,b   Yoshimura, Akihiko ^d   Chien, Kenneth R ^a,b   Knowlton, Kirk U ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENZYME INHIBITOR; JANUS KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENTEROVIRUS; HEART DILATATION; HEART INJURY; HOST RESISTANCE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS INFECTION;

EID: 0037330278     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16491     Document Type: Article

References (47)

1. Rose, N.R. 2000. Viral damage or "molecular mimicry" - placing the blame in myocarditis. Nat. Med. 6:631-632.
2. Liu, P., Mattino, T., Opavsky, M.A., and Penninger, J. 1996. Viral myocarditis: balance between viral infection and immune response. Can. J. Cardiol. 12:935-943.
3. Baboonian, C., Davies, M.J., Booth, J.C., and McKenna, W.J. 1997. Coxsackie B vituses and human heart disease. Curr. Top. Microbiol. Immunol. 223:31-52.
4. Badorff, C., et al. 1999. Enteroviral ptotease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5:320-326.
5. Knowlton, K.U., and Badorff, C. 1999. The immune system in viral myocarditis: maintaining the balance. Circ. Res. 85:559-561.
6. Liu, P., et al. 2000. The tyrosine kinase p561ck is essential in coxsackievirus B3-mediated heart disease. Nat. Med. 6:429-434.
7. Muller, U., et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264:1918-1921.
8. Sen, G.C. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55:255-281.
9. Ihle, J.N. 1995. Cytokine receptor signalling. Nature. 377:591-594.
10. Darnell, J.E., Jr. 1997. STATs and gene regulation. Science. 277:1630-1635.
11. Leonard, W.J., and O'Shea, J.J. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322.
12. O'Shea, J.J., Gadina, M., and Schreiber, R.D. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109:S121-S131.
13. Starr, R., et al. 1997. A family of cytokine-inducible inhibitors of signalling. Nature. 387:917-921.
14. Naka, T., et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:924-929.
15. Endo, T.A., et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:921-924.
16. Alexander, W.S., et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:597-608.
17. Yasukawa, H., Sasaki, A., and Yoshimura, A. 2000. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:143-164.
18. Yasukawa, H., et al. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-1320.
19. Nicholson, S.E., et al. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA. 97:6493-6498.
20. Yasukawa, H., et al. 2001. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J. Clin. Invest. 108:1459-1467. doi:10.1172/JCI200113939.
21. Auernhammer, C.J., and Melmed, S. 2001. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J. Clin. Invest. 108:1735-1740. doi:10.1172/JCI200114662.
22. Lutton, C.W., and Gauntt, C.J. 1985. Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice. J. Interferon Res. 5:137-146.
23. Wessely, R., Klingel, K., Knowlton, K.U., and Kandolf, R. 2001. Cardioselective infection with coxsackievitus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation. 103:756-761.
24. Knowlton, K.U., Jeon, E.S., Berkley, N., Wessely, R., and Huber, S. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenorype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70:7811-7818.
25. Kishimoto, C., Kitazawa, M., Hiraoka, Y., and Takada, H. 1997. Extracellular matrix remodeling in coxsackievirus B3 myocarditis. Clin. Immunol. Immunopathol. 85:47-55.
26. Hanakawa, Y., Amagai, M., Shirakata, Y., Sayama, K., and Hashimoto, K. 2000. Different effects of dominant negative mutants of desmocollin and desmoglein on the ceil-cell adhesion of keratinocytes. J. Cell Sci. 113:1803-1811.
27. Wang, Y., et al. 1998. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-2168.
28. Samulski, R.J., Chang, L.S., and Shenk, T. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63:3822-3828.
29. Auricchio, A., Hildinger, M., O'Connor, E., Gao, G.P., and Wilson, J.M. 2001. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene Ther. 12:71-76.
30. Henke, A., Huber, S., Stelzner, A., and Whitton, J.L. 1995. The role of CD8+ T lymphocytes in coxsackievitus B3-induced myocarditis. J. Virol. 69:6720-6728.
31. Tanaka, N., et al. 1996. Transthoracic echocardiogtaphy in models of cardiac disease in the mouse. Circulation. 94:1109-1117.
32. Kanegae, Y., et al. 1995. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res. 23:3816-3821.
33. Hanada, T., et al. 2001. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. J. Biol. Chem. 276:40746-40754.
34. Cook, D.N., et al. 1995. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science. 269:1583-1585.
35. Tanaka, T., et al. 2001. Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J. Mol. Cell. Cardiol. 33:1627-1635.
36. Kanda, T., et al. 1996. Modification of viral myocarditis in mice by interleukin-6. Circ. Res. 78:848-856.
37. Shioi, T., et al. 1997. Protective role ofinterleukin-12 in viral myocarditis. J. Mol. Cell. Cardiol. 29:2327-2334.
38. Schmidtke, M., et al. 2000. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis. J. Med. Virol. 61:518-526.
39. Okuno, M., et al. 2000. Expressional patterns of cytokines in a murine model of acute myocarditis: early expression ofcardiotrophin-1. Lab. Invest. 80:433-440.
40. Sheng, Z., et al. 1997. Cardiotrophin I (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J. Biol. Chem. 272:5783-5791.
41. Hirota, H., et al. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 97:189-198.
42. Wollert, K.C., et al. 1996. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hyperrrophy. Assembly ofsarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J. Biol. Chem. 271:9535-9545.
43. Marine, J.C., et al. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 98:609-616.
44. Flodstrom, M., et al. 2002. Target cell defense prevents the development of diabetes after viral infection. Nat. Immunol. 3:373-382.
45. Grerch, D. 2001. Mechanism of interferon resistance in hepatitis C. Lancet. 358:1662-1664.
46. Btinckmann, A., et al. 2002. Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br. J. Cancer. 86:449-455.
47. Sakamoto, H., et al. 1998. A Janus kinase inhibitor, JAB, is an interferongamma-inducible gene and confers resistance to interferons. Blood. 92:1668-1676.